PAPER Lublin A, Isoda F, Patel H, Yen K, Nguyen L, Hajje D, Schwartz M, Mobbs C

FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp and protect against proteotoxicity.

PLoS One. 2011;6(11):e27762. PubMed: 22114686

PAPER Funke SA

Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.

Int J Alzheimers Dis. 2011;2011:151645. PubMed: 22114742

PAPER Malm T, Koistinaho J, Kanninen K

Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.

Int J Alzheimers Dis. 2011;2011:517160. PubMed: 22114743

PAPER Nacmias B, Reitz C, Arendt T

Early clinical and molecular detection of Alzheimer's disease.

Int J Alzheimers Dis. 2011;2011:818639. PubMed: 22114746

PAPER Patel S, Shah RJ, Coleman P, Sabbagh M

Potential peripheral biomarkers for the diagnosis of Alzheimer's disease.

Int J Alzheimers Dis. 2011;2011:572495. PubMed: 22114744

PAPER Lautner R, Mattsson N, Schöll M, Augutis K, Blennow K, Olsson B, Zetterberg H

Biomarkers for microglial activation in Alzheimer's disease.

Int J Alzheimers Dis. 2011;2011:939426. PubMed: 22114747

PAPER Cristalli DO, Arnal N, Marra FA, de Alaniz MJ, Marra CA

Peripheral markers in neurodegenerative patients and their first-degree relatives.

J Neurol Sci. 2012 Mar 15;314(1-2):48-56. PubMed: 22113180

PAPER Firbank MJ, Allan LM, Burton EJ, Barber R, O'Brien JT, Kalaria RN

Neuroimaging predictors of death and dementia in a cohort of older stroke survivors.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):263-7. PubMed: 22114300

PAPER Nardone R, Bergmann J, Christova M, Caleri F, Tezzon F, Ladurner G, Trinka E, Golaszewski S

Effect of transcranial brain stimulation for the treatment of Alzheimer disease: a review.

Int J Alzheimers Dis. 2012;2012:687909. PubMed: 22114748

Didier Pitsi

Bristol-Myers Squibb
Belgium

Maria Aderuza Horst

Brazil

Christa Avampato

New York, United States

Pampa Saha

Indian Institute of Chemical Biology
Kolkata, India

Ileana Sulea

Romania

DC: Where Does TDP-43’s Toxic End Really Come From?

CONFERENCE COVERAGE 2011-11-25 Conference Coverage Clearly, the C-terminal of TDP-43 has something to do with amyotrophic lateral sclerosis (ALS). The toxic fragments appear as aggregating, 25- and 35-kiloDalton (kDa) species that supposedly result from cleavage by caspase 3 or another